Photo from wikipedia
Belvarafenib is active in BRAF- and NRAS-mutant tumors, but acquired ARAF mutations drive resistance. Click to show full abstract
Belvarafenib is active in BRAF- and NRAS-mutant tumors, but acquired ARAF mutations drive resistance.
Keywords:
mutations limit;
limit response;
raf dimer;
araf mutations;
dimer inhibition;
response raf
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!